Ondantriwa (Ondansetron)

Ondansetron, the active ingredient in Ondantriwa, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondantriwa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways. - Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute episodes. - Radiation‑induced nausea and vomiting: Helps prevent the onset of nausea. - Post‑operative post‑operative nausea and vomiting (PONV): Decreases the incidence of postoperative vomiting. - Pregnancy ? ? ?. -   - 

....

....